Inhibition of gastric and pancreatic secretion in dogs by CGRP: Role of somatostatin

W. S. Helton, M. M. Mulholland, N. W. Bunnett, H. T. Debas

Research output: Contribution to journalArticlepeer-review


The coexistence of calcitonin gene-related peptide (CGRP) and somatostatin (SS) within the stomach and pancreas and the potent inhibitory effects of both peptides on exocrine secretions from these organs suggest that they are functionally related. To assess the potential role of SS in the mediation of CGRP action, the effects of intravenous human CGRP (64, 132, and 264 pmol · kg-1 · h-1) and somatostatin-14 (SS-14; 100, 400, and 800 pmol · kg-1 · h-1) on plasma levels of SS immunoreactivity (SS-IR) and on pentagastrin-stimulated gastric and pancreatic secretion were compared in conscious dogs. CGRP caused significant inhibition of gastric acid (85-102%), pancreatic protein (63-86%), and pancreatic bicarbonate (74-89%) outputs and a simultaneous dose-related rise (40-102 fmol/ml) in plasma SS-IR. Cessation of CGRP infusion resulted in prompt return of plasma SS-IR to basal levels and an increase in gastric and pancreatic secretion. Although CGRP is a potent releasor of SS into the circulation, its inhibitory action on gastric acid secretion cannot be explained solely by a rise in plasma SS-IR. In the pancreas, in contrast to the stomach, inhibition appears to be more closely related to a rise in circulating level of SS-IR.

Original languageEnglish (US)
Pages (from-to)19/4
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Issue number4
StatePublished - 1989

ASJC Scopus subject areas

  • Physiology
  • Hepatology
  • Gastroenterology
  • Physiology (medical)


Dive into the research topics of 'Inhibition of gastric and pancreatic secretion in dogs by CGRP: Role of somatostatin'. Together they form a unique fingerprint.

Cite this